# Correction: Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors

**Authors:** Sanjay Adhikary, Subrata Roy, Shailesh Budhathoki, Siam Chowdhury, Abbey Stillwell, Alexei G. Basnakian, Alan Tackett, Nathan Avaritt, Mohamed Milad, Mohammad Abrar Alam

PMC · DOI: 10.1039/d5md90014j · RSC Medicinal Chemistry · 2025-04-03

## TL;DR

This paper corrects a previously published study on new drug compounds that may help treat melanoma by targeting cell structure proteins.

## Contribution

The paper provides corrections to a prior study on thiazole-fused derivatives as potential melanoma treatments.

## Key findings

- The paper corrects errors in the original study's data or methodology.
- The corrections may impact the interpretation of the compounds' effectiveness against melanoma.

## Abstract

Correction for ‘Thiazole-fused androstenone and ethisterone derivatives: potent β- and γ-actin cytoskeleton inhibitors to treat melanoma tumors’ by Sanjay Adhikary et al., RSC Med. Chem., 2025, 16, 1105–1130, https://doi.org/10.1039/d4md00719k.

## Linked entities

- **Proteins:** actb (actin beta), Act5C (Actin 5C)
- **Diseases:** melanoma (MONDO:0005105)

## Full-text entities

- **Diseases:** melanoma tumors (MESH:D008545)
- **Chemicals:** androstenone (MESH:C000214), ethisterone (MESH:D005003), Thiazole (MESH:D013844)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11966533/full.md

---
Source: https://tomesphere.com/paper/PMC11966533